OBSERVATIONAL STUDY OF TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION POSITIVE (EGFRM plus ) ADVANCED OR RECURRENT NON-SMALL-CELL LUNG CANCER (NSCLC), AFTER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE THERAPY WITH EGFR TYROSINE KINASE INHIBITORS (EGFR-TKI)

被引：0
|
作者：
Kunitoh, Hideo [1 ]
Tanai, Chiharu [2 ]
Hosomi, Yukio [3 ]
Yoh, Kiyotaka [4 ]
Goto, Yasushi [5 ]
Ohashi, Yasuo [6 ]
机构：
[1] Mitsui Mem Hosp, Tokyo, Japan
[2] Ntt Med Ctr, Div Respirol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[5] Tokyo Univ Hosp, Dept Resp Med, Tokyo, Japan
[6] Univ Tokyo, Dept Biostat, Tokyo 1138654, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; progression; RECIST; beyond PD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-011
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [21] Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer
    Wang, Zhi-jie
    An, Tong-tong
    Mok, Tony
    Yang, Lu
    Bai, Hua
    Zhao, Jun
    Duan, Jian-chun
    Wu, Mei-na
    Wang, Yu-yan
    Li, Ping-ping
    Sun, Hong
    Yang, Ping
    Wang, Jie
    CHINESE JOURNAL OF CANCER RESEARCH, 2011, 23 (02) : 112 - 117
  • [22] The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
    Sgambato, A.
    Casaluce, F.
    Maione, P.
    Rossi, A.
    Rossi, E.
    Napolitano, A.
    Palazzolo, G.
    Bareschino, M. A.
    Schettino, C.
    Sacco, P. C.
    Ciadiello, F.
    Gridelli, C.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (20) : 3337 - 3352
  • [23] CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
    Vansteenkiste, J.
    Reungwetwattana, T.
    Nakagawa, K.
    Cho, B. C.
    Cobo Dols, M. A.
    Cho, E. K.
    Bertolini, A.
    Bohnet, S.
    Zhou, C.
    Lee, K. H.
    Nogami, N.
    Okamoto, I.
    Leighl, N.
    Hodge, R.
    McKeown, A.
    Brown, A. P.
    Rukazenkov, Y.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28 : 189 - 189
  • [24] The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer
    Chen, Dougfang
    Chu, Tianqing
    Chang, Qing
    Zhang, Yanwei
    Xiong, Liwen
    Qiao, Rong
    Teng, Jiajun
    Han, Baohui
    Zhong, Runbo
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (09)
  • [25] PHARMACOECONOMIC ASPECTS OF DIFFERENT INHIBITORS OF TYROSINE KINASE IN FIRST-LINE THERAPY OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH A MUTATION IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) GENE
    Ryazhenov, V. V.
    Gorokhova, S. G.
    Gorokhov, V
    VALUE IN HEALTH, 2016, 19 (07) : A720 - A720
  • [26] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Dwan, Kerry
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Jain, Pooja
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (05):
  • [27] First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer
    Greenhalgh, Janette
    Boland, Angela
    Bates, Victoria
    Vecchio, Fabio
    Dundar, Yenal
    Chaplin, Marty
    Green, John A.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (03):
  • [28] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    CANCER RESEARCH, 2006, 66 (08)
  • [29] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [30] CYTOKERATIN 19 FRAGMENT (CYFRA21-1) PREDICTS THE EFFICACY OF THE EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR (EGFR-TKI) IN NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING EGFR MUTATION
    Tanaka, K.
    Hata, A.
    Kaji, R.
    Fujita, S.
    Takeshita, J.
    Matsumoto, T.
    Monden, K.
    Nagata, K.
    Nanjo, S.
    Otsuka, K.
    Tachikawa, R.
    Otsuka, K.
    Hayashi, M.
    Tomii, K.
    Katakami, N.
    ANNALS OF ONCOLOGY, 2012, 23 : 137 - 138
12345